Answers are grounded in this paper and cite their sources.
There have been published case reports for these adverse events. Healthcare providers should be aware of the possibility of lichen sclerosis and lichen planus developing in patients receiving ICIs which could necessitate hospitalization or discontinuation. Regulatory agencies are advised to monitor the risks as a potential safety signal.
No takes yet. Share an insight, caveat, or question.
Alharbi et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: